Key Takeaways
- Broad-based 20% revenue growth: Revenue rose 19.9% YoY with all three verticals contributing, led by a 45% jump in exports off a small base.
- CDMO volume engine intact: The 17.8% CDMO growth was almost entirely volume-driven, with API price movements netting out across a 400-API portfolio.
- Margins inched up, but no timeline for more: Gross margin expanded 71 bps and EBITDA margin 70 bps YoY; management sees further expansion coming but won't say when.
- Plant 6 is the next growth unlock: The INR 40-50 crore refurbishment is on track for phase-wise commercialization late in FY26, taking revenue capacity toward INR 1,000 crores.
- What to watch next quarter: The pace of injectable capacity utilization, any inorganic move now that M&A exploration is acknowledged, and whether Trade Generics' quarter-to-quarter lumpiness smooths out.
Revenue Growth & Composition
- CDMO: Grew 17.8% YoY to INR 160 crores, driven by customer additions, portfolio expansion and consistent delivery; growth was mostly volume-driven with a very small price component.
- Trade Generics & Institutional: Grew 25.2% YoY to INR 44 crores on enhanced distribution reach, stronger presence in underserved regions and a wider product range; quarter-to-quarter variation is normal due to tender shipment timing and seasonal effects in a still-small base.
- Exports: Grew 45.4% YoY to INR 6 crores with no one-off element, as the company deepens its presence in Rest of Asia, CIS and Africa; management advises judging the long-term trend, not any single quarter.
- Client concentration improving: Growth is distributed across clients, with the contribution of the top customer consistently declining over the last 4-5 years.
- API price dynamics: The company deals with close to 400 APIs; when API prices fall, volumes tend to rise, so the net impact on growth percentages is muted; all facilities handle general category products, not antibiotics, so price fluctuations are less severe.
Komal Gupta: "If everyone is wanting to give us the credit, we did work more to deliver this kind of growth. We agree."
Margin & Cost Structure
- Margin expansion: Gross margin expanded 71 bps YoY to 38.3%, EBITDA margin improved 70 bps to 12.6%, though management calls the exact timing of further expansion difficult to pin down.
- Depreciation tailwind: Depreciation fell sequentially because the injectables facility uses the WDV method, where initial years carry higher depreciation that reduces over time; some reduction also came from Plant 2 extension assets.
- Injectable margin potential: On a fully developed business, injectable gross margins are higher than the company average; pure injectable CDMO players operate at 18-21% EBITDA margins, per an analyst's math.
- Segment margins similar: Management stated the margin profile stays similar across CDMO, Trade Generics and exports, with no significant divergence worth disclosing.
Komal Gupta: "Exactly when the correct operational efficiency balance along with the revenue and capacity expansion hits is difficult to mention the timeline, but we see margins growing as you have been seeing consistently."
Capacity Expansion: Plant 6 & Injectables
- Plant 6 refurbishment: Acquired and now in the refurbishment phase; the INR 40-50 crore CapEx plan is on track with 2-3 more quarters of mechanical work expected, followed by a validation period.
- Phase-wise commercialization: Some areas may be brought up sooner to deliver benefit this year, but the facility in all areas and sections will mostly come up next year (FY27); depreciation will begin when capitalization occurs, likely at the fag end of FY26.
- Revenue capacity: With existing plants plus Plant 6 capitalized, the company should be able to deliver INR 1,000 crores in revenue aside from injectables, with further upside possible later through efficiency improvements.
- Injectable utilization: Capacity utilization is improving quarter-on-quarter, though management declined to disclose specific Q1 revenue numbers; the injectable facility enhances the ability to serve diverse customer needs across a wider product range.
- Injectable Phase II trigger: Expansion will be considered only after Plant 6 is successfully finished and when the injectable facility nears peak utilization, roughly a INR 100 crore revenue run rate; adding capacity would take about a quarter or two depending on machinery.
Trade Generics: Competitive Dynamics & Distribution
- More entrants, more acceptance: The entry of more companies into trade generics is increasing overall acceptance of the category and removing the perception of poor quality; branded generic companies face cannibalization issues when entering this space.
- Distribution build-out: The company is building toward 5,000-6,000 distributors using a nucleation and growth model, with no specific timeline given; management is committed to growing this vertical strongly.
- No winner-takes-all market: Management pointed to Leeford building a business of similar size to Cipla's trade generics presence in just 15 years, despite Cipla's 40-year head start, as evidence that the market can accommodate multiple scaled players.
Hitesh Windlass: "The goal is never to have a winner takes all. And in these complicated markets, Cipla is, even though it's been around for 40 years, but Leeford is also about the same size, which they have built in the last 15 years."
Exports & Regulatory Progress
- Dossier pipeline: The company is adding more dossiers, securing registrations and renewing existing products across Rest of Asia, CIS and Africa; in-licensing of certain marketing authorizations for Europe is in process with regulatory filings completed.
- No timeline from regulators: Management cautioned that most regulatory authorities do not give timeline commitments, so commercialization depends on when approvals come through; optimism remains about expanding the exports vertical as filings unlock.
- Long-term view: With exports at INR 6 crores and growing 45% YoY, management advises looking at long-term trends rather than quarterly numbers, and confirmed there was no one-off element in the quarter's growth.
Strategy & Capital Allocation
- M&A exploration active but nothing imminent: The company has been exploring M&A transactions but has not come across anything solid and is not in the final stages of any opportunity.
- Organic CapEx fallback: If no inorganic opportunity materializes after injectables stabilization and Plant 6 is running, the company would deploy CapEx on its own for another dosage form.
- Dosage form strategy: Any new dosage form must cater to all three verticals: Trade Generics, Institution, CDMO and exports; potential areas include steroids, hormones, soft gel capsules, inhalers, eye drops and ointments.
- Dividend policy maintained: The board paid INR 5.8 per share for FY25, consistent with the policy of distributing close to 20% of profit; the company hopes to continue this in future.
- Schedule M tailwind: Management reiterated its listing thesis that increasing quality pressures in the highly fragmented contract manufacturing industry should benefit organized players like Windlas, though wallet share from customers is impossible to quantify because no published data exists and customers do not disclose it.
Hitesh Windlass: "Our strategy is that as we add a dosage form, it should cater to all 3 of our verticals. So we have to be able to use it in TGx Institution, in CDMO as well as in exports."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Plant 6 mechanical refurbishment | 2-3 more quarters of work, then validation | Phase-wise commercialization late FY26; full facility FY27 |
| Revenue capacity post-Plant 6 | INR 1,000 crores aside from injectables | When Plant 6 is fully capitalized (FY27) |
| Injectable Phase II expansion | Triggered when near peak utilization (~INR 100 crore revenue run rate) | ~2 quarters from trigger; only after Plant 6 is finished |
| Dividend payout | Continue distributing close to 20% of profit | Ongoing, subject to board approval |
| Organic CapEx for next dosage form | If no M&A materializes after injectables stabilize and Plant 6 is running | No date (conditional on two prior milestones) |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue | ₹210 cr, +20% YoY |
| EBITDA | ₹27 cr, +27% YoY |
| PAT | ₹18 cr, +31% YoY |
| EPS | ₹8.4, +30% YoY |
| Gross margin | 38.3%, expanded 71 bps YoY |
| EBITDA margin | 12.6%, improved 70 bps YoY |
| CDMO revenue | ₹160 cr, +17.8% YoY |
| Trade Generics & Institutional revenue | ₹44 cr, +25.2% YoY |
| Exports revenue | ₹6 cr, +45.4% YoY |
| Dividend paid | ₹12.2 cr (₹5.8 per share) for FY25, paid in August 2025 |
| Plant 6 CapEx plan | ₹40–50 cr, on track |
| Peak revenue potential (ex-injectables) | ₹1,000 cr, once Plant 6 is capitalized |
| Peak revenue potential (including injectables) | ₹1,100 cr, with possible upside from efficiency gains |
| Depreciation | Decreased sequentially; current run rate is base for FY26 before Plant 6 capitalization |